MedDataX Logo

The Effect of PD01 on Cardiovascular Health and Microbial Environment

NCT ID: NCT02622425

Last Updated: 2016-12-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

62 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-06-30

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This randomized, placebo-controlled trial aims to determine the effects of daily administration of a carotenoid-producing Bacillus strain PD01 over a 6-week period on cardiovascular health biomarkers, microbiota composition and functioning and intestinal barrier function in overweight subjects.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Overweight Obesity

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Carotenoid Bacillus Microbiota Cardiovascular health

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PD01

Carotenoid-producing Bacillus strain PD01

Group Type ACTIVE_COMPARATOR

PD01

Intervention Type DIETARY_SUPPLEMENT

Carotenoid-producing Bacillus strain PD01

Placebo

Maltodextrin

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

maltodextrin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo

maltodextrin

Intervention Type DIETARY_SUPPLEMENT

PD01

Carotenoid-producing Bacillus strain PD01

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Overweight men/women (BMI 25-35 kg/m2)
* Healthy individuals
* Age between 18 and 70 years
* Fasting glucose \< 7.0 mmol/L
* Normal HbA1c (4.4 to 6.2%)

Exclusion Criteria

* Type 2 diabetes mellitus (defined as fasting plasma glucose ≥ 7.0 mmol/L);
* History of (severe) cardiovascular, respiratory, urogenital, gastrointestinal/hepatic, hematological/immunologic, HEENT (head, ears, eyes, nose, throat), dermatological/connective tissue, musculoskeletal, metabolic/nutritional, endocrine, neurological diseases, allergy, major surgery and/or laboratory assessments which might limit participation in or completion of the study protocol.
* Abdominal surgery interfering with gastrointestinal function, upon judgment of the principle investigator)
* Use of medication interfering with endpoints
* Use of antioxidants, minerals and vitamin supplements available in pharmacies, drugstores, food markets or in alternative medicine
* Administration of investigational drugs or participation in any scientific intervention study which may interfere with this study (to be decided by the principle investigator), in the 180 days prior to the study
* Use of antibiotics in the 90 days prior to the start of study
* Known pregnancy, lactation
* Abuse of products; alcohol (\> 20 alcoholic consumptions per week) and drugs
* Smoking
* Blood donation within 3 months before study period
* Plans to lose weight or following a hypocaloric diet during the study period;
* Weight gain or loss \> 3 kg in previous 3 months
* High physical activity (\>4.5 hours of running/week)
* Hormone replacement therapy (women)
* History of any side effects towards intake of pro- or prebiotic supplements of any kind
* History of any side effects towards intake of carotenoids
* Prohibited use of pro-, pre- or synbiotics during study period and from one month prior to start of study.
* High intake of fruits and vegetables (more than the 75th percentile of dietary intake of fruits and vegetables)
* Vegetarians/vegans
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Maastricht University Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Bouke Salden

MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ad Masclee, MD

Role: PRINCIPAL_INVESTIGATOR

Maastricht University Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

MUMC+

Maastricht, Limburg, Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

153001

Identifier Type: -

Identifier Source: org_study_id